Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

ual report on Form 10-K for the year ended Dec. 31, 2006, as well as TorreyPines Therapeutics' subsequent filings with the Securities and Exchange Commission. TorreyPines Therapeutics undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    Company Contact:                               Investor Contact:
    Paul Schneider                                 Rhonda Chiger
    TorreyPines Therapeutics, Inc.                 Rx Communications
    858-623-5665, x125                             917-322-2569
    pschneider@torreypinestherapeutics.com         rchiger@rxir.com


'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... mayo de 2015 Dipexium Pharmaceuticals, ... farmacéutica de fase tardía centrada en el ... 0.8%), y colaboradores de investigación clínica, han ... el diseño innovador de los ensayos pivotales ... evalúan Locilex®, su nuevo péptido de antibiótico ...
(Date:5/22/2015)... 2015  Effective staffing of key marketing services ... success. Research and consulting leader ... pharmaceutical and biotech marketing managers with metrics detailing ... are being channeled into marketing operations of global ... utilize this report to benchmark their own resource ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
... Sciences International, Inc. (Nasdaq: BDSI ) announced ... Officer of BDSI, will present at the Jeffries Global ...  The presentation is scheduled for Thursday, June 9 at ... http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on ...
... bioTheranostics, Inc., a bioMerieux company that develops innovative ... today findings from clinical studies utilizing the company,s ... the studies were presented this week at the ... Meeting in Chicago. On June 6, ...
Cached Medicine Technology:BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 2BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 3Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting 2Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting 3
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... 2015 Omar Ahmad Barrada, a junior ... in the 2015 Congress of Future Medical Leaders in ... gathering of “America’s highest achieving high school students.” , ... set new goals and learn better study habits,” said ... during which we can ask the surgeons questions.” , ...
(Date:5/22/2015)... “It’s like learning an new language,” ... President of Clinical Operations/Education and Training at Harmony ... how care is coded and reimbursed.” , Harmony ... reimbursement, operations and compliance consulting, as well as ... a new series of day-long seminars on the ...
(Date:5/22/2015)... Massachusetts (PRWEB) May 22, 2015 ... is a difficult process. Historically providers have not ... by payers. Starting in 2015, Medicare has paved ... coordination activities. Thanks to the launch of ... providers and health systems using the platform will ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship of ... is in his second year of racing in the professional ... Fire Department in Missoula, MT. He entered the triathlon scene ... career, he has had 15 1st Place finishes. In his ... in all seven of his 2014 races, including two 2nd ...
Breaking Medicine News(10 mins):Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... million people in the U.S., some 480,000 of them in ... be stricken with the disease. The overall burden of dementia ... 80 percent of dementia cases. Yet as ... have a tremendous impact on family members, friends and caregivers. ...
... American Cancer Society (ACS), the American Society for Colposcopy ... Clinical Pathology (ASCP) have released new guidelines for the ... generally advise a reduction in the number of tests ... they receive the benefits of testing while minimizing the ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) -- ... other efforts to get people to quit smoking prevented close to ... United States, a new study shows. The findings, published online ... , likely represent just the tip of the iceberg as lung ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) -- ... called actinic keratosis, which is a common precursor to squamous ... treatments took weeks or even months to treat the condition, ... can work in a matter of days, according to the ...
... in cigarette smoking among Americans since the mid-1950s ... the U.S. Surgeon General,s Report on Smoking and Health ... cancer deaths between 1975 and 2000, according to a ... Center., Results of the National Cancer Institute-funded study, conducted ...
... , WEDNESDAY, March 14 (HealthDay News) -- People who don,t ... likely to become obese, according to a new study. ... were studied for eight nights. Half of the participants got ... half got only two-thirds of their typical amount of sleep ...
Cached Medicine News:Health News:UCLA to launch unique, comprehensive Alzheimer's and dementia care program 2Health News:UCLA to launch unique, comprehensive Alzheimer's and dementia care program 3Health News:Health groups issue cervical cancer screening guidelines 2Health News:Health groups issue cervical cancer screening guidelines 3Health News:Anti-Smoking Efforts Saved 795,000 Lives Over 25 Years: Study 2Health News:Anti-Smoking Efforts Saved 795,000 Lives Over 25 Years: Study 3Health News:New Gel Treats Precancerous Skin Condition in Days: Study 2Health News:Study: US tobacco-control efforts prevented nearly 800,000 cancer deaths between 1975 and 2000 2Health News:Lack of Sleep May Give You the Munchies 2
... features of the Mastercycler ep Extremely ... blocks with SteadySlope technology Intuitive graphic ... device, a Mini-Satellite system, or a PC-controlled ... (Electronic Sample Protection) Optional motorized lid for ...
... is the cycler that revolutionized thermal ... and swappable blocks ensure consistent results, ... rugged machine is more than just ... new features and upgrades as research ...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Medicine Products: